Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Dx Firm Atlas Genetics Lands $4.1M in VC Funds

NEW YORK (GenomeWeb News) – Atlas Genetics has gained £2.1 million ($4.1 million) in venture capital from previous and new investors, which it will use to conduct clinical evaluations for a clinical diagnostic test for Group B Streptococcus in pregnant women.
 
Investors in this round of financing included South West Ventures Fund, GEIF, and private investors through the SWAIN business angel’s network. New investors included Finance South West Growth Fund and Braveheart Ventures.
 
Atlas, a spin-out from Bath University in the UK, is developing a point-of-care portable system to deliver molecular diagnostic results in 30 minutes. The firm is working on tests for meningitis, Chlamydia, Group B Streptococcus and for methicillin-resistant Staphylococcus aureus.
 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.